| Bradlee N Novotny, D.c., P.c. | |
|
4401 N 7th St, Lincoln, NE 68521-2425 | |
| (402) 476-8619 | |
| (402) 476-8634 |
| Full Name | Bradlee N Novotny, D.c., P.c. |
|---|---|
| Type | Facility |
| Speciality | Physical Medicine & Rehabilitation |
| Location | 4401 N 7th St, Lincoln, Nebraska |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073723425 | NPI | - | NPPES |
| Provider Name | Bradlee N Novotny |
|---|---|
| Provider Type | Practitioner - Chiropractic |
| Provider Identifiers | NPI Number: 1821018573 PECOS PAC ID: 3476623869 Enrollment ID: I20080528000044 |
News Archive
While cholesterol levels, blood pressure, blood glucose levels and weight have been used to measure the risk of death due to heart diseases till now, a new parameter has emerged – the pulse rate.
An international team of scientists led from Sweden's Karolinska Institutet has for the first time mapped all the genes that are activated in the first few days of a fertilized human egg. The study, which is being published in the journal Nature Communications, provides an in-depth understanding of early embryonic development in human - and scientists now hope that the results will help finding for example new therapies against infertility.
ChemoCentryx, Inc. today announced that CCX140, the Company's novel, orally active CCR2 antagonist successfully met its primary endpoint of safety and tolerability and demonstrated clinical efficacy in a Phase II study in patients with type 2 diabetes on stable doses of metformin.
Harbor BioSciences, Inc. today announced that new data from the Phase I/IIa clinical trial of the company's lead drug candidate Apoptone®, its anticancer drug candidate being developed for prostate cancer, will be presented as part of the Scientific Program in a General Poster Session at the American Society of Clinical Oncology (ASCO) Annual Meeting.
› Verified 4 days ago
| Provider Name | Kelsey M Novotny |
|---|---|
| Provider Type | Practitioner - Chiropractic |
| Provider Identifiers | NPI Number: 1124434576 PECOS PAC ID: 8729206271 Enrollment ID: I20140826001495 |
News Archive
While cholesterol levels, blood pressure, blood glucose levels and weight have been used to measure the risk of death due to heart diseases till now, a new parameter has emerged – the pulse rate.
An international team of scientists led from Sweden's Karolinska Institutet has for the first time mapped all the genes that are activated in the first few days of a fertilized human egg. The study, which is being published in the journal Nature Communications, provides an in-depth understanding of early embryonic development in human - and scientists now hope that the results will help finding for example new therapies against infertility.
ChemoCentryx, Inc. today announced that CCX140, the Company's novel, orally active CCR2 antagonist successfully met its primary endpoint of safety and tolerability and demonstrated clinical efficacy in a Phase II study in patients with type 2 diabetes on stable doses of metformin.
Harbor BioSciences, Inc. today announced that new data from the Phase I/IIa clinical trial of the company's lead drug candidate Apoptone®, its anticancer drug candidate being developed for prostate cancer, will be presented as part of the Scientific Program in a General Poster Session at the American Society of Clinical Oncology (ASCO) Annual Meeting.
› Verified 4 days ago
| Provider Name | Tanner J Burt |
|---|---|
| Provider Type | Practitioner - Chiropractic |
| Provider Identifiers | NPI Number: 1700484573 PECOS PAC ID: 9739599606 Enrollment ID: I20201104000349 |
News Archive
While cholesterol levels, blood pressure, blood glucose levels and weight have been used to measure the risk of death due to heart diseases till now, a new parameter has emerged – the pulse rate.
An international team of scientists led from Sweden's Karolinska Institutet has for the first time mapped all the genes that are activated in the first few days of a fertilized human egg. The study, which is being published in the journal Nature Communications, provides an in-depth understanding of early embryonic development in human - and scientists now hope that the results will help finding for example new therapies against infertility.
ChemoCentryx, Inc. today announced that CCX140, the Company's novel, orally active CCR2 antagonist successfully met its primary endpoint of safety and tolerability and demonstrated clinical efficacy in a Phase II study in patients with type 2 diabetes on stable doses of metformin.
Harbor BioSciences, Inc. today announced that new data from the Phase I/IIa clinical trial of the company's lead drug candidate Apoptone®, its anticancer drug candidate being developed for prostate cancer, will be presented as part of the Scientific Program in a General Poster Session at the American Society of Clinical Oncology (ASCO) Annual Meeting.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Bradlee N Novotny, D.c., P.c. 4401 N 7th St, Lincoln, NE 68521-2425 Ph: (402) 476-8619 | Bradlee N Novotny, D.c., P.c. 4401 N 7th St, Lincoln, NE 68521-2425 Ph: (402) 476-8619 |
News Archive
While cholesterol levels, blood pressure, blood glucose levels and weight have been used to measure the risk of death due to heart diseases till now, a new parameter has emerged – the pulse rate.
An international team of scientists led from Sweden's Karolinska Institutet has for the first time mapped all the genes that are activated in the first few days of a fertilized human egg. The study, which is being published in the journal Nature Communications, provides an in-depth understanding of early embryonic development in human - and scientists now hope that the results will help finding for example new therapies against infertility.
ChemoCentryx, Inc. today announced that CCX140, the Company's novel, orally active CCR2 antagonist successfully met its primary endpoint of safety and tolerability and demonstrated clinical efficacy in a Phase II study in patients with type 2 diabetes on stable doses of metformin.
Harbor BioSciences, Inc. today announced that new data from the Phase I/IIa clinical trial of the company's lead drug candidate Apoptone®, its anticancer drug candidate being developed for prostate cancer, will be presented as part of the Scientific Program in a General Poster Session at the American Society of Clinical Oncology (ASCO) Annual Meeting.
› Verified 4 days ago